Navigation Links
AMRI Hires George Svokos as Senior Vice President Sales and General Manager - API
Date:1/10/2014

ALBANY, N.Y., Jan. 10, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) today announced the appointment of George Svokos, to the newly created position of Senior Vice President Sales and General Manager API, effective January 6, 2014. Mr. Svokos will report to William S. Marth, President and Chief Executive Officer.

"Mr. Svokos is a strategic thinker who comes to AMRI with years of experience in pharmaceutical manufacturing, business development, R&D, and sales and marketing," said Mr. Marth. "With his experience handling a large sales force in a multibillion dollar business, Mr. Svokos' main focus is to develop a commercial strategy around active pharmaceutical ingredients (APIs), as well as to assist on the sales side of the business."

Before coming to AMRI, Mr. Svokos had been with Teva Pharmaceuticals Industries Ltd. since 1979. Most recently, he was Senior Vice President of Product and Portfolio Selection, and Business Development, responsible for strategic planning, portfolio selection, new product introductions and business development. From 2011 to 2012, Mr. Svokos was Senior Vice President, US Technical Operations, responsible for strategic planning, manufacturing, supply chain, regulatory and legal compliance, and safety, for eleven U.S. dosage form manufacturing facilities, as well as supply of branded and generic products to the U.S. market from overseas plants in Europe, the Middle East, China and India. Before this role, he served as Executive Vice President of Commercial Operations, Teva API, leading the global sales and marketing of Teva's API division, including a global sales force, with multibillion-dollar sales. Mr. Svokos is the Senior Vice President of the Drug, Chemical & Associated Technologies Association (DCAT) and will become President next year.

Mr. Svokos earned a Master's degree in Business Administration from the University of Missouri and a Bachelor's of Science degree in Chemical Engineering from Columbia University.

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 22 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


'/>"/>
SOURCE Albany Molecular Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Hires Vijay Kumar Batra as Managing Director, AMRI India
2. FPR Specialty Pharmacy Hires Slomski To Lead Sales And Marketing; Moves To Next Phase In Cleveland Clinic Trials
3. inviCRO hires Stefan Linehan as Director of Ex Vivo Research & Imaging Services
4. Xcelience hires Clinical Supplies VP; Opens Birmingham, UK Site
5. Preventice hires Kevin Nickels as chief operating officer
6. Medolac Hires Doug Hawkins as Senior Executive
7. Spectrum Orthotics And Prosthetics Hires New Practitioner
8. SynGen Hires Former Pall Medical Executive as President of Cord Blood Business Unit
9. BioSante Hires VP of New Business Development and Contract Manufacturing and Announces New Appointment to Board of Directors
10. Tris Pharma Hires President for Generic Pharmaceuticals Business
11. United Medical Credit Hires More Staff to Contact Doctors and Promote their Financing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):